logo

iStock Rating

C
Details...
Enter Symbol click to research

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

Sector: Medical

Current Price : $77.87

52 Week Low
$38.8852 Week High
$85.60
 

VERTEX PHA(NSDQ:VRTX)
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)
# Employees: 2200
Address: 130 WAVERLY STREET,CAMBRIDGE,MA,USA
Phone: 6173416100
Fax: 617-576-2109
Website: www.vrtx.com
Email: investorinfo@vrtx.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Jeffrey M. Leiden (Chair of the Board; President and Chief Executive)
Ian F. Smith (Executive Vice President and Chief Financial Offic)
Paul M. Silva (Senior Vice President and Corporate Controller)
David Altshuler (Director)
Joshua S. Boger (Director,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 3/31/2013
Next Earnings Date(Expected): 8/5/2013
Mean EPS (Next Qtr): ($0.21)
Mean EPS (Year): ($2.23)
Mean Estimate(Long Term): $19.00
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 10
Shares Performance
Period VRTX Compare to S&P
YTD 91.67 % 68.04 %
4 Weeks 1.03 % 3.56 %
12 Weeks 49.44 % 43.03 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1544127
Shares Outstanding: 221M
Market Cap: $17.78B
52 Week High: $85.60
52 Week Low: $38.88
P/E Ratio: 669.250
PEG Ratio: -0.010
Split: On 8/24/2000 VRTX split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -50.00 %
EPS Growth in Last Year: -127.91 %
Sales Growth in Last Quarter: -1.68 %
Sales Growth in Last Quarter: -25.16 %
Financials
Qtr Book Value: $18.68
Cash Flow/Share: $96.78
Change in Payout Ratio: -0.010
Price/Sales: 12.550
Home | Login |Research | Earnings | Scans | Stock Charts | Chart School | Glossary |Submit Article | Join Blog Network | Advertise | Subscribe to RSS

Terms of Use | Privacy Policy | Copyright 2012 all rights reserved
Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia. Advertisement partners Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.